{"name":"NoNO Inc.","slug":"nono-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Nerinetide (NA-1)","genericName":"Nerinetide (NA-1)","slug":"nerinetide-na-1","indication":"Acute ischemic stroke (within 24 hours of symptom onset)","status":"phase_3"},{"name":"NoNO-42","genericName":"NoNO-42","slug":"nono-42","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Nerinetide (NA-1)","genericName":"Nerinetide (NA-1)","slug":"nerinetide-na-1","phase":"phase_3","mechanism":"Nerinetide is a peptide that inhibits postsynaptic density protein 95 (PSD-95) to reduce excitotoxic neuronal death following ischemic stroke.","indications":["Acute ischemic stroke (within 24 hours of symptom onset)"],"catalyst":""},{"name":"NoNO-42","genericName":"NoNO-42","slug":"nono-42","phase":"phase_3","mechanism":"NoNO-42 is a nitric oxide (NO) donor compound designed to increase nitric oxide bioavailability in target tissues.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNdldLTmhhTU90SGtkZGg2bDc0TDlCR2RHU0xMcUV3NTlsY21CX0ZQRGl6TmFqQXZ1dmdVV25aaTdZY1otcUNtWjNrd3NYdlpxSUc2VjNhOGhWeXJMYWg0V3dvR3pxOThQYmlheUpzUkZLUFNVdlRCcWZFNDZDWDJfd2JqUHAyRXJHRk56UVJDemZXTVZ3VVRwSWdSUFY0dDVS?oc=5","date":"2025-09-15","type":"pipeline","source":"bnnbloomberg.ca","summary":"Julien Nono-Womdim’s Top Picks for September 15, 2025 - bnnbloomberg.ca","headline":"Julien Nono-Womdim’s Top Picks for September 15, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPeFNQb0hoTGhieXZVV0o3SG9KUmo0QVdHdjhfblEwMi1TTGR4VHl0UmRoVnJSMi0wSU5OdGMtMkJ0dTJDX1pQX3R2Z2R1WU5hcHVGYXo5cVBoRmp2bEtWNWZTR082aTNxamRqdnIxMnBpQkNvSHBFWFNsYVk1cGg3WlNtV3JzWDhmTFlRVERGelpLNnpfOWZLWF9KaVBoWGZFcnNGYjNubw?oc=5","date":"2025-02-18","type":"pipeline","source":"Cumming School of Medicine","summary":"UCalgary stroke researchers find silver linings in neuroprotection studies - Cumming School of Medicine","headline":"UCalgary stroke researchers find silver linings in neuroprotection studies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQTmtmNmg1aV9YaFNYdkdLemYzRWUyU2tRd05TaVVQRkFfLUliVlZVOVViUmcxYkctUDZSdXlSZmtRczFtQ3hlb3dNcDdoZEpwN0xyZlVRRTlla1NjWUxxcXd1V2oxcHN3cFNuVTJGOW5zeExYb2N4bUh3N3pUcE54QXZ3eVZsS1RBVVNMeFNEdmZjZnc5bUtWLWE2WG41X2RQV3h6SlhDLTVxUzRNNmfSAbMBQVVfeXFMUFdvZ1NyLXVHUGxoWlFCZi1Fdk9hdEdhLXZYZk9Ebm5lNWc5eHBZQXRPQXZDXzljelowd01GLWhJQUxDcWNWbG5sdlU5eHZPRU05WE1yNllzcnlaNktaZUZGRllrRUlucmZ4UGtBQnhhT3duaDVZNy1SMmw3ZTVOZDE1Y0k3UmZLY1lOdG44Q0x2dm9GTzk4LVBZc0dod3pnWHRwSWpkMkk4eHVMTUZXSEFOVm8?oc=5","date":"2024-11-29","type":"pipeline","source":"Inquirer.net","summary":"Pharmally exec lied about ties to Lin Weixiong, birth record shows – solon - Inquirer.net","headline":"Pharmally exec lied about ties to Lin Weixiong, birth record shows – solon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxORndHY3daWUhJWEJGMnZieF93aEs4TW12UXkzV0QxVU1BR2NjZGtmVkhOV0lIZWw2a3o5Z1VMTW9DTnBJZUFIblRGMnJrUThVZk9Sa1Y1UnlIazhCTmx4RlpFTm1GLWNJXzNubGhWbldzQzFYcGN0MmhpZkItMXljYXNoV0RfZEJZeEx1MmxIcmZDd3VibllsOF9CZ0xYLV9ZR0d5U3F3TFRHMURrZmdZTWVzX0Jldkhyam5BVnR2V2h5eUxLbUJOTGxMQUpnb0s0TDBpVEV5Ni12eFQzc3o0R2hyVQ?oc=5","date":"2024-06-06","type":"pipeline","source":"prnewswire.com","summary":"Global Carotid Artery Stent Market to Grow Substantially at a CAGR of ~3% by 2030 | DelveInsight - prnewswire.com","headline":"Global Carotid Artery Stent Market to Grow Substantially at a CAGR of ~3% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQSWdSOHBwaGwtdE80eUJ4cVJteEg0VHE4M3hCdzNxcG5rQ05ZRU9LeUJGMEw4WU9tMnp0VXFib3lpUmJLenNJTl9kY2h6ZkNLdlVHSUx4WkhLa1BOSEwxcU5qR1FndXhPeFlHVDVLZUVlZWdENUJPWmhJMzhRR1RVcVVEWjhJV1pUZ0VGa29ZUDd6NnJEUU1jcDdYaVdzZ0txWkJjVUxiNUkzZllsek9oTk00dGVSakVKemFDa0xodGh5aDlXQ2xma0l5UUZ4azM1dnlfSDFPVnV2ZnBaQmc?oc=5","date":"2024-06-04","type":"pipeline","source":"prnewswire.com","summary":"Global Thrombectomy Devices Market to Witness Growth at a CAGR of ~5% by 2030 | DelveInsight - prnewswire.com","headline":"Global Thrombectomy Devices Market to Witness Growth at a CAGR of ~5% by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNMVlXcUFpQ0hwZVBYa1VqS1R1SWx6cGhSTk9rTXg4Y29PN3pYekNQZWJicnNXeU9UQWNwaW1idzl2ajBiTmYwSG80cDlMcnB1YzI1YUs3d1F2YVZCVkZjTnFzWlpPMzNOTXQtclpyX0c1cmRITE1lYmR2RWItOVpuaHA5TQ?oc=5","date":"2023-12-21","type":"pipeline","source":"BioSpace","summary":"Opinion: Space Is the Next Frontier in Drug Discovery - BioSpace","headline":"Opinion: Space Is the Next Frontier in Drug Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSEg1a0xzZjk2U2JEaWhGRGtoMUc0RkRSbERyM05ob19wcnFvRVBmMzZ4QjBLU3MwdFlZUkNja1ZFVW1oNmVHNGJVTGoyTU1MQUVkZ2tvTFlZZmdjU2dKN1pzUkdKMVB1bFNZc3lmNzlYX2t2bllfelhrVG84Sm0zRkk2QXZ2ZTZqcHUxZ2Rqc0lUSGJfRWdtaEFKbkpTRU0zRXFfbHRxMUw0a3NueVN1ejZWckZKZw?oc=5","date":"2023-03-09","type":"pipeline","source":"newswire.ca","summary":"Covalon Welcomes Martin Goldfarb, O.C., to its Board of Directors - newswire.ca","headline":"Covalon Welcomes Martin Goldfarb, O.C., to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPRUxWUlJ5OFROalFMMmpRS01wWEptRkltWHNBb3o4OUMyVjNKZzRLYmJ1dzFoMFRoWDBwUldWTTAxXzY2LVRsRW0wdGdVTnh5RF9LRVV0N0JCenVVZHg4SUxseTZjZ1E2dnl5SE1jcUdCZ0lDekc1dXlpRHMxZDRKUFRUVHlTVkt6RUlOd3pJT2xIUWdwYXM2S0h0NFBpOWU0MzJETzR5dlBlVHdDWjJiRjhyNzEyZ2dCVEJkUGJXWVkwdw?oc=5","date":"2021-09-10","type":"deal","source":"facebook.com","summary":"Rappler. . Senators on Friday, September 10, agree to summon Rose Nono Lin, one of the business associates of the President’s former economic adviser, Michael Yang, who is involved in questionable pan","headline":"Rappler. . Senators on Friday, September 10, agree to summon Rose Nono Lin, one of the business associates of the Presid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOMERoTDNJdFE1Mm5lQlZfMnI4clhZUVpuUTBvXzNRSE9ER2F6SVZVLXNhVlR0U2FVRVJCQi1sc1VqNUNDYkM3TWZhRUVwR2NpOHA1aUdXTnVJUjRsV05icDdzMjFnRnNudl9OUF82QzU5ZVA2aldWMDNudmdERFRXR243anNzM3o1ZFZ6Y1I1QlVfY19jbEZzbE5kU1VBNTBKU191aktubGdvaGNLRldMdnZnRFhYYjdtUzR2ZjhPelNZRHFFek5rMUFwazdneTFMZ0g3b1FwQzk?oc=5","date":"2020-02-21","type":"pipeline","source":"Medical Professionals Reference","summary":"Nerinetide, Without Prior Alteplase, Improved Functional Outcome in Acute Ischemic Stroke - Medical Professionals Reference","headline":"Nerinetide, Without Prior Alteplase, Improved Functional Outcome in Acute Ischemic Stroke","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOcUZROWE1ZUhCS1VqX0Ytb2tWWXo4OG1ycWxycklMX1FlY1NOZ3Njc2VITkRXX09hWl9VRzNTNkJLTHBQYk9nWF9odFlJNkgtakstbGpWbEV5NFNWSlp0UXYxbldTc0RwUl83dXpGTjhCZ1NfT2lNVVpDVnhGa0hhMGNYMnRhSzZaU3dSd2RvODRYX0FFN0JxV2VpNFJGTTBtYUVnUUxDWVpJSDZIQ2JZUnVsenBOUQ?oc=5","date":"2020-02-20","type":"pipeline","source":"The Globe and Mail","summary":"‘A pivotal moment’: Canadian-developed drug shows dramatic outcomes in reducing damage caused by strokes - The Globe and Mail","headline":"‘A pivotal moment’: Canadian-developed drug shows dramatic outcomes in reducing damage caused by strokes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNUDRRQUFfd19ENk9ocEZzcGJwaEJOOEVEWDIzbHF4a29Tb3Y1dUE3cmk0bk5RdEItZFF3VTNndnV1cWZyMEpCcC14ai1TZzJJeFhheTN4U2NqV2I1amlfM1MtMnR1X0tydEJHaDI1bzhXd2FmNnlwdDZlX0dickhRQTlCNmZBdkZaU2FJ?oc=5","date":"2019-11-22","type":"pipeline","source":"qz.com","summary":"The future of stroke patients may depend on the part-time job of a Canadian surgeon - qz.com","headline":"The future of stroke patients may depend on the part-time job of a Canadian surgeon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQUEN2WUlTWk91OTJ2dTYyMXdwdGNjQWh2SDVGVzZsdmZMb1BnUzl1MGc4amtrRUVrc1lSbVJjOHFLVGxiRFN0UjRKemxyWERNQmpxY01tN2NHZXJDSFEzNG9IdmNkUWZjakpWUm1IMWJMSHRfYzVvSk1qaUdoWUliQ1Y2SDVzQWM0bGxpbk9JUFgtY1dF?oc=5","date":"2014-09-15","type":"pipeline","source":"U.OSU","summary":"Joshua Josephson, OD – Class of 1968 – Notable Alumnus | 100 Years of Great Vision! - U.OSU","headline":"Joshua Josephson, OD – Class of 1968 – Notable Alumnus | 100 Years of Great Vision!","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}